

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 October 2022 (27.10.2022)



(10) International Publication Number
WO 2022/224278 A1

(51) International Patent Classification:

A61K 31/506 (2006.01) C07C 255/54 (2006.01)
A61K 31/445 (2006.01) C07D 211/40 (2006.01)
A61K 31/4545 (2006.01) C07C 217/58 (2006.01)
C07C 217/86 (2006.01)

(21) International Application Number:

PCT/IN2022/050381

(22) International Filing Date:

22 April 2022 (22.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

202141018688 22 April 2021 (22.04.2021) IN

(71) Applicant: JUBILANT PRODEL LLC [US/US]; 1430
US Highway 206, Suite 110, Bedminster, New Jersey, New
Jersey 07921 (US).

(72) Inventor; and

(71) Applicant: RAJAGOPAL, Sridharan [IN/IN]; Jubilant
Therapeutics India Ltd, # 96, Industrial Suburb, 2nd
Stage, Industrial Area, Yeshwanthpur, Karnataka, Banga-
lore 560022 (IN).

(72) Inventors: SADHU, Naveen; Jubilant Therapeutics In-
dia Ltd, # 96, Industrial Suburb, 2nd Stage, Industrial
Area, Yeshwanthpur, Karnataka, Bangalore 560022 (IN).
SIVANANDHAN, Dhanalakshmi; Jubilant Therapeutics
India Ltd, # 96, Industrial Suburb, 2nd Stage, Industrial
Area, Yeshwanthpur, Karnataka, Bangalore 560022 (IN).
MOHD, Zainuddin; Jubilant Therapeutics India Ltd, # 96,
Industrial Suburb, 2nd Stage, Industrial Area, Yeshwanth-
pur, Karnataka, Bangalore 560022 (IN).

(74) Agent: LAKSHMIKUMARAN, Malathi et al.; B6/10,
Safdarjung Enclave, New Delhi 110029 (IN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,

NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(54) Title: COMPOUNDS AS PD1/PD-L1 INHIBITORS AND METHODS THEREOF



(57) Abstract: The present invention relates in general, to the field of pharmaceutical compounds, more particularly to the compounds of Formula (I) which acts as inhibitors for PD1/PD-L1 interaction. The present invention further relates to a method of preparation of compounds of Formula (I). The present invention also relates to a composition of compounds of Formula (I).

WO 2022/224278 A1